A Full Service Intellectual Property Firm
Safeguarding innovation demands proactive IP counsel known for thought leadership and creative legal strategies. Safeguarding innovation demands Oblon.
Six Oblon Partners named “IP Stars” by Managing Intellectual Property Magazine
Oblon is proud to announce that six partners have been named “IP Stars” by Managing Intellectual Property's magazine.
Oblon Welcomes New Patent Professionals
Oblon welcomes back Senior Attorney Soumya (Soum) Panda and Stephen McBride who also joins the Firm's Electrical/Mechanical (E/M) Practice Group. Oblon will also welcome two summer associates on May 21. “We are always looking for young talent with knowledge of the latest cutting edge technologies,” said Philippe Signore, Managing Partner at Oblon
Yorikatsu Hohokabe Receives Service Recognition Certificate at the International Management & Delegates Meeting in San Diego
The Firm is proud to report that Yorikatsu Hohokabe was awarded Service Recognition Certificate as an individual award by the Past-President, Ms. Patricia Bunye (on behalf of the President, Mr. Peter Hess) at the International Management & Delegates Meeting held on April 30, 2018 in San Diego.
Sequenom v. Ariosa: The Saga Continues…
Three years after a previous legal battle between Sequenom and Ariosa ended in a difficult loss for Sequenom (in what some commentators have characterized as a misapplication of the holding in Mayo Collaborative Services v. Prometheus Laboratories, Inc., 132 S. Ct. 1289 (2012))
Anacor Pharmaceuticals, Inc. v. Iancu
On May 14, 2018, in Anacor v. Iancu,the Federal Circuit issued its opinion affirming the Board’s invalidation of Anacor’s tavaborole patent. The patent-in-suit, U.S. Patent No. 7,582,621, entitled “Boron-containing Small Molecules,” is directed to the use of tavaborole to treat fungal infections.
“Clearing Out Invalid Patents” Insufficient for Declaratory Judgment Jurisdiction
In the recent AIDS Healthcare Foundation v. Gileadopinion, the Federal Circuit considered whether AHF’s desire to “‘clear out the invalid patents’ so that it ‘would have the ability then to partner with generic makers’” immediately upon expiration of the five-year NCE exclusivity for the antiviral agent tenofovir alafenamide fumarate (TAF) was sufficient to give rise to declaratory judgment jurisdiction. It was not.
Joint International Symposium on U.S. and European Patent Practice
The Oblon and Maiwald firms are pleased to invite you to a complimentary: Joint International Symposium on U.S. and European Patent Practice to be presented in two convenient locations / dates:
- Tokyo: Monday, June 18, 2018 at the Fukuracia Marunouchi Oazo
- Osaka: Thursday, June 21, 2018 at the Osaka Science & Technology Center
41th LES Japan Annual Meeting 2018 in Sapporo, Japan
Philippe Signore, Yuki Onoe, and Yorikatsu Hohokabe will be representing Oblon at the 41th LES Japan Annual Meeting 2018 in SAPPORO, Japan on July 6-7,2018.
Infopat in Tokyo, Japan 2018
Philippe Signore has been invited to speak at Infopat in Tokyo, Japan on July 13, 2018. His presentation will focus on updates on recent US Patent Practice.
Chambers & Partners USA: America’s Leading Lawyers for Business
Oblon’s Intellectual Property practice received a prestigious Band 1 ranking from Chambers & Partners USA (2015). The publication identified the firm as a leading firm in the area of intellectual property law, while also ranking four Oblon partners.
Oblon Named a "Best Law Firm" by U.S. News and World Report
Oblon was named one of the “Best Law Firms” in the United States in 2017 by U.S. News and World Report and Best Lawyers.
Oblon Honored in The Legal 500 United States 2015
Oblon has been honored by The Legal 500 as one of America's leading firms in the area of patent prosecution for utility and design patents. In addition to the firm ranking, six Oblon partners were mentioned for their individual expertise and praised the distinguished Post-Grant proceedings team.